Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.71 |
| ▸ | STAT6 | P42226 | 2/20 | 0.34 |
| ▸ | MMP3 | P08254 | 7/20 | 0.32 |
| ▸ | MMP1 | P03956 | 3/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 7/20 | 0.31 |
| ▸ | MMP2 | P08253 | 8/20 | 0.30 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57913 | 1.00 | TUBB1 (0.71) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL58329 | 0.92 | TUBB1 (0.69) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL6805710 | 0.91 | TUBB1 (0.77) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL58126 | 0.91 | TUBB1 (0.68) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL58290 | 0.91 | TUBB1 (0.74) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL58627 | 0.91 | TUBB1 (0.68) | TUBB1STAT6MMP3MMP1MMP9 | |
| SCHEMBL13585986 | 0.91 | TUBB1 (0.68) | TUBB1STAT6MMP3MMP1MMP9 | |
| Taltobulin SCHEMBL6799555 | 0.89 | TUBB1 (0.81) | TUBB1STAT6MMP3MMP1MMP9 | |
| Taltobulin SCHEMBL57119 | 0.89 | TUBB1 (0.81) | TUBB1STAT6MMP3MMP1MMP9 | |
| Taltobulin SCHEMBL6670481 | 0.89 | TUBB1 (0.81) | TUBB1STAT6MMP3MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885STAT6 4739/4885MMP3 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.